News
ALKS
--
0.00%
--
Alkermes Plc (ALKS) Investor Presentation - Slideshow
The following slide deck was published by Alkermes plc in conjunction with this event.
Seekingalpha · 2d ago
The Daily Biotech Pulse: Roche's COVID Combo Therapy Reduces Need For Ventilation, ESMO Presentations
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 17)
Benzinga · 5d ago
Alkermes ALKS 4240 shows encouraging action in solid tumors
Alkermes (ALKS) +1% presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered interleukin-2 variant immunotherapy, ALKS 4230, administered intravenously as monotherapy and in combination with the
Seekingalpha · 5d ago
Alkermes presents new clinical data on ALKS 4230 in mini oral presentation at ESMO
Alkermes (ALKS) +1% presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered interleukin-2 variant immunotherapy, ALKS 4230, administered intravenously as monotherapy and in combination with the
Seekingalpha · 5d ago
Alkermes 4230 shows encouraging single-agent activity
Alkermes (ALKS) +1% presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered interleukin-2 variant immunotherapy, ALKS 4230, administered intravenously as monotherapy and in combination with the
Seekingalpha · 5d ago
Alkermes Will Present New Clinical Data On ALKS 4230 For IL-2 Variant Immunotherapy At European Society For Medical Oncology Sept. 18
Alkermes plc (NASDAQ:ALKS) today presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, ALKS 4230,
Benzinga · 6d ago
Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual Congress
Alkermes plc (Nasdaq: ALKS) today presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered interleukin-2 (IL-2) variant immunotherapy, ALKS 4230, administered intravenously as monotherapy and in combination with the PD-1 inhibitor pembrolizumab
PR Newswire · 6d ago
20 Most Drug Infested Cities in the U.S.
In this article we will present the list of 20 most drug infested cities in the U.S. (click to skip ahead and see the top 5 cities with the most overall drug use). The 20 most drug infested cities in the US are a reminder that drugs are indeed a major problem in the US. The […]
Insider Monkey · 09/14 17:06
Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience
Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at the Psych Congress 2020 Virtual Experience, held Sept. 10-13, 2020. The company presented six posters, one of which focused on new outcomes research
PR Newswire · 09/14 12:00
What Type Of Returns Would Alkermes'(NASDAQ:ALKS) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Spare a thought for...
Simply Wall St. · 09/13 13:59
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
Alkermes to Take Part in Cantor Virtual Global Healthcare Conference
PR Newswire · 09/09 21:00
Alkermes To Present New Data On Investigational Immuno-Oncology Candidate, ALKS 4230, At 2020 European Society For Medical Oncology (ESMO) Virtual Congress
DUBLIN, Sept. 8, 2020 /PRNewswire/ --Alkermes plc(NASDAQ:ALKS) today announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 (IL-2) variant
Benzinga · 09/08 11:06
Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
Alkermes plc (Nasdaq: ALKS) today announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the European Society for Medical Oncology (ESMO) Virtual Congress, taking place Sept. 18-21, 2020. Safety and anti-tumor
PR Newswire · 09/08 11:00
Why Is Alkermes (ALKS) Down 12% Since Last Earnings Report?
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 08/28 16:31
Entera Osteoporosis Trial, And Other News: The Good, Bad And Ugly Of Biopharma
Entera Bio reports encouraging data from osteoporosis trial. Alkermes progresses Phase 2 trial for ALKS 4230.
Seeking Alpha - Article · 08/24 10:48
ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?
ANIK vs. ALKS: Which Stock Is the Better Value Option?
Zacks · 08/21 16:40
Alkermes shares are trading lower. The company announced the FDA Advisory Committee will review its New Drug Application for ALKS 3831. The review is tentatively scheduled for October 9th.
Benzinga · 08/21 16:24
Alkermes under modest pressure ahead of Ad Com review of schizo drug
Alkermes plc (ALKS -1.9%) is down in early trade, albeit on very light volume, on the heels of the news that an FDA advisory committee will meet on October
Seeking Alpha - Article · 08/21 13:55
FDA Ad Com October 9 for Alkermes drug for schizophrenia and bipolar disorder
The FDA's Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee will meet virtually on Friday, October 9,
Seeking Alpha - Article · 08/21 11:14
Webull provides a variety of real-time ALKS stock news. You can receive the latest news about Alkermes through multiple platforms. This information may help you make smarter investment decisions.
About ALKS
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
More